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Glioblastoma multiforme (GBM) is one of the most aggressive types of brain cancer, characterized by rapid pro-
gression, resistance to treatments, and low survival rates; the development of a targeted treatment for this dis-
ease is still today an unattained objective. Among the different strategies developed in the latest few years for
the targeted delivery of nanotherapeutics, homotypic membrane-membrane recognition is one of the most
promising and efficient. In this work, we present an innovative drug-loaded nanocarrier with improved targeting
properties based on the homotypic recognition of GBM cells. The developed nanoplatform consists of boron ni-
tride nanotubes (BNNTs) loaded with doxorubicin (Dox) and coated with cell membranes (CM) extracted
from GBM cells (Dox-CM-BNNTs). We demonstrated as Dox-CM-BNNTs are able to specifically target and kill
GBM cells in vitro, leaving unaffected healthy brain cells, upon successful crossing an in vitro blood-brain barrier
model. The excellent targeting performances of the nanoplatform can be ascribed to the protein component of
the membrane coating, and proteomic analysis of differently expressed membrane proteins present on the CM
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ofGBMcells and of healthy astrocytes allowed the identification of potential candidates involved in the process of
homotypic cancer cell recognition.
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1. Introduction
The extremely high mortality rate that characterizes glioblastoma
multiforme (GBM) makes this tumor one of the deadliest types of can-
cer, and thus a great challenge for oncologists and biomedical scientists.
Although surgery leads to an acceptable alleviation of the symptoms
and to a relatively increased life expectancy, the high aggressiveness,
the almost universal recurrence, the complex levels of heterogeneity,
and the diffuse infiltration tendency of GBM make the treatment of
this disease extremely complicated, being thus still characterized by
an extremely poor prognosis [1].
Chemotherapy and/or radiotherapy are also used as adjuvant thera-
pies. In this context, doxorubicin (Dox) represents an effective chemo-
therapy agent, which, however, requires a precise delivery to the
tumor site in order to contain its significant side-effects (gastrointesti-
nal toxicity, myelosuppression, cardiotoxicity, and neurotoxicity)
[2–4]. Dox has been shown to be toxic on glioblastoma cell lines
in vitro, and indeed good performances have been also obtained on
in vivomodels [5–8], although an efficient targeting system is still re-
quired [9].
In recent years, medical research has focused on drug delivery sys-
tems and targeted solutions in order to improve drug bioavailability,
specifically in proximity of the tumor mass in order to reduce drug tox-
icity profile [10,11]. The systemic administration of anti-cancer drugs
suffers not only from the lack of selectivity, but also from scarce bio-
availability, low tumor penetration, limited effectiveness, and from the
necessity of repeated administrations with consequent remarkable
side effects. The main limitation for the treatment of glioblastoma
using anticancer drugs lies on the inability of themajority of these com-
pounds to cross the blood-brain barrier (BBB), which is responsible for
the selective transport of small molecules like glucose and amino
acids, as well as of small lipid-based substances, from the lumen of the
blood capillaries to the extracellular matrix of the central nervous sys-
tem [12,13]. Nanoparticle-based drug delivery systems, such as, for ex-
ample, carbon nanotubes, liposomes, or polymeric nanoparticles, offer
several advantages with respect to the conventional administration
strategies, including an increment of the BBB crossing rate [14], an im-
proved drug targeting/accumulation at tumor level, an enhanced anti-
cancer efficacy, and a lower toxicity in healthy tissues [15–17].
An emerging biocompatible nanoplatform for drug delivery is repre-
sented by boron nitride nanotubes (BNNTs), structural analogs of car-
bon nanotubes. Due to their excellent mechanical and electric
properties, and to their chemical stability, BNNTs have been suggested
to be used in nanocomposites for the development of advanced func-
tional materials and as novel piezoelectric materials. BNNTs, compared
to carbon nanotubes, show a more favorable biocompatibility profile,
and based on the current evidence, they can be considered non-toxic
[18–20]. Although BNNTs find applications in many fields, their use in
the biomedical domain was firstly limited due to their poor solubility
in aqueous solvents, because of their high hydrophobicity. Nevertheless,
a few attempts based on non-covalent coatings of BNNTs using syn-
thetic or natural polymers demonstrated their potential use in
nanomedicine. BNNTs are usually coated with amphiphilic polymers
to impart stability in water [21]; their hydrophobicity can be however
used to loadhydrophobic drugs in their hollow cavity or on their surface
[22]: in a recent work, they have been used for example to encapsulate
Dox for anti-cancer treatment [23].
Many different ligands have been exploited to promote the targeting
of thenanovectors to glioblastomacells.Molecular “Trojan horses”, such
as folic acid, angiopep-2 peptide, and antibodies against transferrin re-
ceptors, represent efficient glioblastoma-targeting ligands able to target
the nanovectors with their cargo to the cancer site [24–26]. However,
the molecular mechanisms involved in cancer recognition are complex
phenomena requiring themultiple binding of different ligands to obtain
a satisfactory targeting level. Moreover, considering the remarkable ge-
netic heterogeneity of glioblastomamultiforme, the targeting efficacy of
the single ligands in different patients is expected to be extremely var-
iable. In this regard, an emerging biomimetic strategy for targeting pur-
poses is the homotypic recognition of tumor cells. This approach
exploits the homotypic affinity between cancer cells, mediated by spe-
cificmembrane proteins, and it relies on the natural properties of cancer
cells in developing strong contacts and adhesive interactions [27–29].
Homotypic targeting is achieved by coating or preparing nanoparticles
with native extract and components of tumor cell membranes, allowing
for the self-recognition with cancer cells [28,30]. This approach also im-
proves the immune tolerance and the nanomaterial stability in biologi-
cal fluids, such as the blood; therefore, besides being an efficient
targeting tool, it also plays a remarkable role for delivery purposes
[31–33]. However, the phenomena involved in the homotypic recogni-
tion are not completely elucidated, and the comprehension of thesemo-
lecular mechanisms may enable the developing of a new generation of
nanovectors enriched on their surfacewith a combination ofmost effec-
tive ligands, in order to improve the targeting efficacy of the
nanotherapeutics.
In this work, we designed and prepared an innovative nanoplatform
consisting of Dox-loaded BNNTs coatedwith GBMcell membrane (Dox-
CM-BNNTs).We demonstratedwithmultiple in vitro tests that the coat-
ing of BNNTs with GBM cell membrane allows selective and efficient
targeting of cancer cells. Dox-CM-BNNTs are preferentially internalized
by GMB cells, where Dox is released and carries out its pro-apoptotic ac-
tion. On the other hand, scarce internalization in astrocytes and neural
cells has been demonstrated. The role of the protein composition in
the nanocarrier targeting has been moreover revealed; finally, the
membrane proteins involved in the cancer homotypic recognition
have been identified by proteomics and gene ontology analysis.
2. Experimental section
2.1. Cell membrane extraction and BNNT coating
U87 MG cells (ATCC HTB-14™) were maintained in high-glucose
(4.5 mg/ml) Dulbecco's modified Eagle's medium (DMEM), supple-
mented with 1% penicillin-streptomycin (P/S), 1% L-glutamine and
10% fetal bovine serum (FBS). Cells were seeded in 10 cm diameter
Petri dishes at a density of 25·103 cells/cm2, and detached with a cell
scraper when reached 90% of confluence. After a centrifugation step
(750 g for 5min), pelletswerewashed twicewithDulbecco's phosphate
buffer saline solution (DPBS). After re-suspension in cold (4 °C) ultra-
pure water, cells were disrupted with a high-pressure homogenizer
(20 psi homogenizing pressure). Samples were centrifuged for 10 min
at 10000 g, the supernatant containing cell membranes was collected
and further centrifuged at 55900 g for 60 min, and the obtained pellet
finally re-suspended in 1 ml of de-ionized water.
5 mg of BNNTs (purchased by BNNT LLC) were dispersed in 5 ml of
cell membrane extract derived from 25·106 cells; coating was achieved
by using an ultrasonic probe (Fisherbrand™ Q125 Sonicator) set at
40W for 30min inside an ice-bath. The cellmembrane-coated boron ni-
tride nanotubes (CM-BNNTs) were collected by centrifugation at 104 g
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for 15 min at 4 °C, and then washed three times with de-ionized water.
The same procedure was used for coating 5 mg of BNNTs with 5 mg of
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-
ethylene glycol)] (mPEG-DSPE), as control sample (mPEG-DSPE-
BNNTs). In order to obtain further control samples, cell membranes
used for BNNT coating were also pre-treated with two proteolytic en-
zymes: 0.5 U/mg proteinase K (Sigma Aldrich) for 8 h at 37 °C and, sub-
sequently, with trypsin EDTA 0.01% (Thermo Fisher) overnight at 37 °C.
After proteolysis, BNNT coating was performed as previously described
to obtain de-proteinated cellmembrane-coated BNNTs (indicated in the
following as CM*-BNNTs). The same procedurewas performed to obtain
protease-treated mPEG-DSPE-BNNTs, as further control (indicated as
mPEG-DSPE*-BNNTs).
2.2. Doxorubicin loading
Dox-loaded BNNTswere obtained by adding 27 μg of Dox (SigmaAl-
drich) to 1 mg of BNNTs in 2 ml of ultra-pure water, sonicating for
30min in ice bath at 20W, and then incubating for 4 h at room temper-
ature. After incubation, samples were centrifuged for 15min at 10000 g
and washed 2 times to remove non-encapsulated Dox. Cell membrane
coating to obtain Dox-CM-BNNTs was performed as described for
plain CM-BNNTs. Estimation of Dox loading inDox-CM-BNNTswas indi-
rectly estimated by assessing the Dox concentrations in the superna-
tants collected during the washing steps. Dox presence was measured
by fluorescence spectroscopy (Agilent Technologies) with an excitation
wavelength of 470 nm and an emission wavelength of 590 nm, by
exploiting a calibration curve (Fig. S1A).
2.3. Nanovector characterization
The morphological characterization of CM-BNNTs and mPEG-DSPE-
BNNTs was performed with bright-field transmission electron micros-
copy (BF-TEM) and high-angle annular dark-field scanning transmis-
sion electron microscopy (HAADF-STEM) imaging, using a FEI Tecnai
G2 F20 TWIN TMP with a Schottky emitter operated at 200 kV.
For energy dispersive spectroscopy (EDS) analysis, samples (pristine
BNNTs, mPEG-DSPE-BNNTs and CM-BNNTs) have been sonicated for
10 min, and 5 μl of each sample have been deposited on a carbon-
coated Cu grid. EDS analyses have been performedusing a Bruker XFlash
6|T30 silicon-drift detector (SDD) with 30 mm2 effective area.
Fourier-transformed infrared spectroscopy (FTIR)was performed on
freeze-dried samples using a Shimadzu Miracle 10 device. The number
of scans was set to 45, the scanning range was set from 4000 to
450 cm−1, and the resolution step at 4 cm−1. The graphs were plotted
using Originpro software, 9.1.
X-ray photoelectron spectroscopy (XPS) analyses were performed
on a Kratos Axis Ultra DLD spectrometer, using a monochromatized Al
Kα source operating at 15 kV and 20 mA. Wide scans were acquired at
an analyzer pass energy of 160 eV, while high-resolution narrow scans
were performed at constant pass energy of 10 eV and steps of 0.1 eV.
The photoelectrons were detected at a take-off angle φ= 0° with re-
spect to the surface normal. The pressure in the analysis chamber was
maintained below 7·10−9 Torr for data acquisition. The data were con-
verted to VAMAS format and processed using CasaXPS software, version
2.3.17.
Thermogravimetric analysis (TGA) was performed using a TGA Q50
device from TA Instruments. The temperaturewas increased from room
temperature to 600 °C with a heating rate of 10 °C/min and under a ni-
trogen flow of 50ml/min. The graphswere plotted usingOriginpro soft-
ware, 9.1.
Dynamic light scattering (DLS) measurements were performed
using a Zeta-sizer NanoZS90 (Malvern Instruments LTD). The measure-
ments were carried out at 37 °C in ultrapure water and in cell culture
medium (DMEM+10% FBS), and the concentration for all the samples
was 100 μg/ml. The Z-potential measurements were carried out in
ultrapure water (pH 5.5), and the conductivity was adjusted in the
range of 30–100 μS/cm. The hydrodynamic diameter and the Z-
potential values represent the mean± SD of 3 different measurements,
with 15 runs for each of them. Before each measurement, the samples
were sonicated for 2 min at 30% amplification (Fisherbrand™ Q125
Sonicator) to avoid the presence of aggregates.
Bicinchoninic acid assay (BCA) Protein Kit (Thermo Scientific) was
used to determine the amount of protein on the cell membrane-
coated surface of the nanovectors, following the manufacturer's proto-
col. Briefly, 25 μl of 100 μg/ml nanotube dispersions (mPEG-DSPE-
BNNTs, CM-BNNT, and CM*-BNNTs) were added in 200 μl of the work-
ing solution. After 30 min of incubation at 37 °C, samples were centri-
fuged for 15 min at 10000 g, and supernatants were collected for
absorbance readings at 560 nm (VICTOR X3 plate reader, Perkin Elmer).
2.4. Proteomics investigation of CM proteins through tandem mass
spectrometry
Mass spectrometry was performed to identify the proteins of CM-
BNNT coating involved in the homotypic targeting of glioblastoma
cells. U87 MG and human primary astrocytes from cerebral cortex
were grown in 10 cm Petri dishes with high-glucose DMEM supple-
mented with 10% FBS and 1% P/S. Mass spectrometry analysis was car-
ried out on U87 MG membrane extracts, healthy astrocyte membrane
extracts (analogously obtained as described for U87 MG membranes),
and coating of CM-BNNTs, since astrocytes represent the healthy cells
that degenerate into glioblastoma upon genetic transformation. The
protein species were identified in each sample withmass spectroscopy;
data-bank consultation was selected grouping proteins present in CM-
BNNT coatings and in U87 MGmembranes but absent in healthy astro-
cyte membranes.
CM-BNNT precipitates and cell membrane pellets were treated with
100 μl of 1% sodium deoxycholate (SDC) surfactant in 50 mM ammo-
nium bicarbonate (Ambic), treated in a Thermomixer at 500 rpm for
10 min at 80 °C, sonicated for 5 min on ice (five cycles of 20 s with
breaks of 40 s), and finally clarified by centrifugation at 16060 g for
10 min at 5 °C. Only in the case of CM-BNNT sample, a further centrifu-
gation step was required for the complete nanotube removal. The pro-
tein concentration in the three sample solutions was determined by
BCA, using bovine serum albumin as standard for the calibration
curve. Subsequently, protein mixtures were reduced and alkylated
using 5 mM dithiothreitol and 20 mM iodoacetamide, respectively,
prior to trypsin digestion at 1:100 (w/w) at 37 °C for 16 h. Digested pro-
tein samples were then treated with 1% trifluoroacetic acid to remove
SDC through acidic precipitation, and supernatants were collected and
desalted using Mobicol spin columns, before liquid chromatography
tandem mass spectrometry analysis. Peptide solutions were dried
under vacuum, dissolved in CH3CN/0.1% HCOOH 2/98 to achieve a
final peptide concentration of 0.5 μg/μl, and dedicated to nanoLC-
nanoESI-MS/MS analysis on an EASY-nLC coupled to an Orbitrap Fusion
mass spectrometer equipped with an EASY-Spray source
(ThermoFisher Scientific). 2 μl of each sample were trapped on a
PepMap C18 precolumn (2 cm × 75 μm i.d., 3μm, 100Å, Thermo Fisher
Scientific) and the separation was then achieved in a PepMap C18 col-
umn (25cm × 75μm i.d., 2μm, 100Å, Thermo Fisher Scientific) heated
at 50 °C at a flow rate of 300 nl/min. In both cases the mobile phases
were CH3CN/0.1% HCOOH 2/98 (phase A) and CH3CN/0.1% HCOOH 98/
2 (phase B). The elution program was the following: 0 min, 5% B;
1 min, 5% B; 105 min, 22% B; 120 min, 32% B; 130 min, 90% B;
145 min, 90% B; 146 min, 5% B; 161 min, 5% B. Mass spectra were ac-
quired in positive ionmode, setting the spray voltage at 2.3 kV, the cap-
illary temperature at 275 °C, and the RF lens at 60%. Data were acquired
in data-dependent mode with a dynamic exclusion of 60 s; survey MS
scans were recorded in the Orbitrap analyzer in the mass range
375–1500m/z at a nominal resolution of 120000 for 200m/z in profile
mode (AGC target 40000; max inject time 50 ms). Data-dependent
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tandemMSanalyseswere performedusing a top-speed approach (cycle
time of 3 s). Ionswere fragmented byHCD (isolationwidth 1.6m/z, nor-
malized collision energy 27%) and analyzed in the IT in centroid mode
(AGC target 2000, max inject time 300 ms). Monocharged ions did not
trigger MS/MS experiments (charge states considered from 2+ to 7+).
To identify peptides, raw data were first converted to .mzML files
using MSConvert tool; X!Tandem and OMSSA search tools were used
to perform protein identification by querying all the fragment ion spec-
tra against the UniProtKB/Swiss-Prot database (Release August 2018;
20386 sequences) using human taxon as database. Aminimumnumber
of three peptides was considered to define an identified protein. False
positive hits were filtered out with FDR b1%. Gene ontology (GO) cellu-
lar component (CC) analysis was performed using the open source Pan-
ther database in order to retrieve proteins involved in cell membrane
structure organization and regulation.
Results of GO (CC) analysis were selected by a “bottleneck” ap-
proach; a group of proteins identified in both CM-BNNTs and U87 MG
cell membranes, but absent in healthy astrocyte membranes, was se-
lected as potential candidates involved in homotypic targeting. A litera-
ture inquirywas carried out on this group to attribute the biological role
of each candidate, and a subsequent intragroup selection of proteins in-
volved in cell-cell and cell-vesicle interaction was performed.
2.5. Doxorubicin release studies
Dox release from Dox-CM-BNNTs was studied at 4 different experi-
mental conditions: at pH 7.4 to mimic healthy extracellular pH, at
pH 7.4 with 100 μM of H2O2 to mimic the intracellular pH in oxidative
stress conditions, at pH 4.5 to mimic the acidic organelle environment
[23], at pH 4.5 with H2O2 100 μM to mimic the cancer cell environment
in oxidative stress conditions. 2 ml of Dox-CM-BNNTs solution (1 mg/
ml) was maintained in a shaker at 140 rpm at 37 °C, protected from
light. The dispersionswere centrifuged (10000 g for 15min) at different
time points (6, 24, 48, 72 and 168 h), and the supernatant was collected
for further analysis, whereas the pellet was readily re-dispersed using
the same solvents and let under shacking at 37 °C for the following
time point measurements. The cumulative amount of the released Dox
in the supernatants was evaluated using fluorescence spectroscopy at
an excitation wavelength of 470 nm and at an emission wavelength of
590 nm. Fluorescence intensitywas then converted into Dox concentra-
tion by using calibration curves obtained at the specific pH and H2O2
conditions of the samples (Fig. S1B).
2.6. Nanovector targeting in static conditions
The in vitro targeting ability of mPEG-DSPE-BNNTs, CM-BNNTs, and
CM*-BNNTs was evaluated under static conditions using 3 different
cell lines: a) neuronal-like cells derived from the SH-SY5Y human neu-
roblastoma cell line (ATCC CRL-2266™), astrocytes type I clone C8D1A
(ATCC CRL-2541™), andU87MG cells (ATCCHTB-14™), all of them cul-
tured at 37 °C, 5% CO2 and 100% humidity.
8 days before the experiments, 3·103 SH-SY5Y cells/cm2 were
seeded on 1.9 cm2 glass coverslips into a 24-well plate with Dulbecco's
Modified Eagle's Medium / Nutrient Mixture F-12 (DMEM/F12; Sigma
Aldrich) supplemented with 10% of FBS and 1% P/S. At 48 h of culture
in proliferative conditions, neural differentiationwas induced by replac-
ing the proliferation medium with high glucose DMEM, 1% FBS, 10 μM
retinoic acid and 1% P/S, similarly as shown in a previous work [34];
cells were maintained in differentiative conditions for 6 days before
performing the targeting experiments. U87 MG and C8D1A cells were
seeded (6·103 cells/cm2) on sterilized glass coverslips into a 24-well
plate with high-glucose DMEM, 10% FBS, 1% P/S, 1% L-glutamine. Nano-
tube targeting was tested by incubating 100 μg/ml of the 3 types of
BNNT samples in 400 μl of complete medium for 6 and 24 h at 37 °C.
After incubation, cells were washed twice with PBS and fixed with 4%
paraformaldehyde (PFA; Sigma Aldrich) for 20 min at 4 °C. Cultures
were stainedwith TRITC-phalloidin (1:100; SigmaAldrich) andHoechst
33342 (1:1000; Invitrogen) in PBS for 30min at 37 °C. Confocal micros-
copy acquisitions were performed using a C2s confocal microscope
(Nikon); nanotubes were imaged with 642 nm laser excitation and
650–750 nm laser emission, similarly as described in a previous work
[35]. Analysis of the signal area (%) of the cells (TRITC-phalloidin) occu-
pied by BNNTs was performed using NIS Elements software (Nikon).
Quantitative analysis of the efficiency of homotypic targeting was
performed through flow cytometry. U87 MG and C8D1A cells were
seeded in 24-well plates (6·103 cells/cm2) and cultured for 24 h before
the experiment. SH-SY5Y were seeded (6·103 cells/cm2) 8 days before
the experiment and induced to differentiation for 6 days before BNNT
incubation.
mPEG-DSPE-BNNTs, CM-BNNTs, and CM*-BNNTs were labeled with
the fluorescent Vybrant™ DiO Cell-Labeling dye (Invitrogen). 20 μl of
DiO was added to 1 mg/ml of nanotube suspension and incubated for
2 h at 37 °C. Samples were thereafter centrifuged (10000 g for
15 min) and washed 3 times, and finally dispersed in phenol red-free
complete medium. 100 μg/ml of the labeled mPEG-DSPE-BNNTs, CM-
BNNTs, or CM*BNNTs were administered to differentiated SH-SY5Y,
C8D1A, and U87 MG cells cultured in 24-well plates. After 24 h of incu-
bation, cells were washed 3 timeswith PBS, treated with 0.05% Trypsin-
EDTA, centrifuged, and suspended in PBS for flow cytometry
measurements.
Cytometry was performed with a Cytoflex device (Cytoflex
Beckmann). Before analyzing the samples with cells, the fluorescence
emissions of 100 μg/ml of mPEG-DSPE-BNNTs, CM-BNNTs, and CM*-
BNNTs were analyzed, and the acquisition gain was calibrated in order
to detect the same fluorescence intensity from the three types of nano-
tube preparation. The maximum fluorescence intensity of non-treated
control cells was used as threshold to discriminate the BNNT-positive
from the BNNT-negative cells.
Inductively-coupled plasma optical emission spectroscopy (ICP-
OES) elemental analysis was performed to quantify the amount of
boron in the cells, and thus to have further quantitative evaluation of
BNNT up-take. SH-SY5Y-derived neurons, C8D1A astrocytes, and U87
MG glioblastoma cells were cultured in T75 flask until reaching 80% of
confluence and then incubated for 24 h with nanotubes (mPEG-DSPE-
BNNTs, CM-BNNTs, and CM*-BNNTs). After nanotube incubation, cells
were washed 5 times with PBS and subsequently detached with 0.05%
trypsin-EDTA and centrifuged to obtain pellets ready for analysis.
ICP was carried out by using an iCAP-7600 DUO (Thermo Fisher Sci-
entific). All chemical analyses performed by ICP-OES were affected by a
systematic error of about 5%. Samples were dissolved in 800 μl of nitric
acid (HNO3 60% v/v) and 200 μl of hydrogen peroxide (H2O2 ≥ 30%) dur-
ing sonication (65 °C for 2 h). Samples were subsequently diluted using
ultrapure water at a final volume of 10 ml; the B concentrations in the
different samples were detected at 249.77 nm, and obtained values
were normalized for the P concentration as representative of the cell
mass (P was detected at 178.28 nm). All measurements have been car-
ried out using a plasma power of 1150 W, a nebulizer gas flow of 0.5 l/
min, a coolflowof 12 l/min, and an auxflowof 0.5 l/min. Concentrations
of BNNTs were calculated from the concentrations of B by considering a
1:1 B to N ratio.
2.7. Nanovector targeting in dynamic conditions
A home-made fluidic bioreactor was used to investigate the
homotypic targeting of CM-BNNTs in dynamic conditions. A scheme of
the bioreactor is given in the supporting information (Fig. S2). Briefly,
the device was fabricated in poly(methyl methacrylate) (PMMA), and
is composed of 3 independent chambers located in 3 channels; each
chamber has been designed to host a glass coverslip of 0.9 cm2. The
cell cultures (differentiated SH-SY5Y, C8D1A astrocytes, and U87 MG
glioblastoma cells) have been seeded and cultured separately on each
glass coverslip, and transferred into the fluidic bioreactor on the day
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of the experiment. More in details, SH-SY5Y cells were seeded (6·103
cell/cm2) 8 days before the experiment on a glass coverslip in prolifera-
tivemedium (DMEM/F12, 10% FBS, 1%P/S) and, 2 days after seeding, the
differentiationwas induced by replacing themediumwith high-glucose
DMEM, 1% FBS, 10 μM retinoic acid and 1% P/S; the cells were main-
tained in these conditions until the beginning of the experiment. U87
MG and C8D1A were seeded 2 days before the experiment at a density
of 6·103 cell/cm2 and cultured with complete medium (high-glucose
DMEM, 10% FBS, and 1% P/S). The bioreactor was connected to a peri-
staltic pump (Ibidi fluidic unit) and perfused with 15 ml of 100 μg/ml
BNNT suspensions in high-glucose DMEM with HEPES and 10% FBS at
a speed flow of 2 ml/min, for 6 h. During the experiment the bioreactor
was placed in an incubator at 37 °C. After 6 h of treatment in dynamic
conditions, cells were washed 2 times with PBS, fixed with PFA (4% in
PBS for 20 min at 4 °C), and finally stained with TRITC-phalloidin and
Hoechst 33342, as previously described. Confocal laser scanningmicros-
copy was performed to evaluate the co-localization signals of BNNTs
and cells.
2.8. Cell uptake mechanism investigation
The internalization pathway of CM-BNNTs in U87 MG glioblastoma
cells was investigated by confocal fluorescence microscopy.
Pinocytosiswas studied by using Cascade Blue hydrazide fluorescent
dye (Invitrogen). Briefly, U87MGcellswere seeded at a density of 5·103
cells/cm2 inWillCo dishes and, after 1 day of culture, were incubated for
24 hwith 200 μl of phenol red-free HEPES-supplemented completeme-
dium with 300 μM of Cascade Blue hydrazide fluorescent dye and
100 μg/ml of CM-BNNTs. The imaging of nanotubes and pinocytosis ves-
icles was carried out with a confocal fluorescence microscope (C2 sys-
tem Nikon), and co-localization analysis was performed by NIS
Elements software [36].
Vesicles positive for caveolin-1 and clathrinwere detected by immu-
nofluorescence followed by confocal microscopy imaging. 100 μg/ml of
CM-BNNTs were administered for 24 h to U87 MG cells previously
seeded in WillCo dishes. Afterwards, cells were fixed with 4% PFA for
20min at 4 °C,washedwith PBS, and incubatedwith a blocking solution
containing 10% goat serum (GS; EuroClone) in PBS. Samples were then
incubated at 37 °C with anti-caveolin-1 primary antibody or anti-
clathrin primary antibody (1:150, Abcam) in PBS with 10% GS; after 3
washing steps with 10% GS in PBS, samples were stained with 488 nm
Alexa-Fluor secondary antibody (1:100; Millipore), TRITC-phalloidin
(1:100; Sigma Aldrich), and Hoechst 33342 (1:1000; Invitrogen). Con-
focal fluorescence microscopy and co-localization analysis were per-
formed as previously described.
The presence of nanovectors in lysosomes and late endosomes was
investigated by using the acidotropic LysoTracker Deep Red dye
(Invitrogen). U87 MG cells were seeded in WillCo dishes at a density
of 5·103 cells/cm2 and subsequently incubated with phenol red-free
HEPES-supplemented DMEM with 10% FBS and 100 μg/ml CM-BNNTs,
for 24 and 72 h. Samples were washed twice with PBS and treated
with LysoTracker (1:2000) in high-glucose complete medium. After
30 min of staining, cells were washed and stained with Hoechst 33342
(1:1000; Invitrogen) for 15 min at 37 °C. Confocal fluorescence micros-
copy and co-localization analysis were performed as previously
described.
2.9. BBB crossing investigation
The BBB crossing ability of mPEG-DSPE-BNNTs and CM-BNNTs was
evaluated under static and dynamic conditions on an in vitro model.
Concerning the experiments in static conditions, a commercial system
was used (cell culture insertswith 3 μmpores for 24-well plate; Falcon).
For testing the BBB crossing in dynamic conditions, a custom designed
system with two chambers separated by a 3 μm pore size membrane
was exploited. The design and the characterization of the BBB fluidic
system are described in a previous paper of our group [37]. Human en-
dothelial cell line hCMEC/D3 were adopted as reliable in vitromodel to
study nanomaterial crossing [38]. Cells were seeded at the density of
5·104 cells/cm2 on the 3 μm pore size membranes in EndoGRO™-MV-
VEGF medium (Millipore) with 5% FBS and 1% P/S. The cells were cul-
tured on the porousmembranes for 4 days before performing the inves-
tigations on nanomaterial crossing. At day 4, BBB characterization was
performed, assessing the trans-endothelial electrical resistance (TEER)
by using a volt-Ohm-meter (Millicell® ERS-2 Millipore). The
nanovector crossing through the BBBwas investigated, as already men-
tioned, both in static and in dynamic conditions by incubating 100 μg/ml
of mPEG-DSPE-BNNTs or of CM-BNNTs in the BBB systems.
Concerning the tests in static conditions, 700 μl of cell medium was
placed in the abluminal compartment (i.e., the bottom of the well),
while the luminal chamber of the insert was filled with 200 μl of me-
dium containing the nanovectors. The concentration of nanovectors in
the abluminal compartment was measured at both 24 h and 72 h with
flow cytometry.
The BBB crossing studies in dynamic conditions were carried out by
applying to the upper chamber of the fluidic system a flow of 12ml/min
(corresponding to a shear stress of 12 dyne/cm2) with a peristaltic
pump (Ibidi fluidic unit system). At 3 h of perfusion, the flow was
stopped and the medium of the upper channel was replaced with
nanovector-freemedium. At 72 h from thenanovector removal, theme-
dium in the abluminal chamber was collected and the nanovector con-
centration measured by flow cytometry.
Calibration curves showing the numbers of events detected by flow
cytometry when testing different amount of nanotubes are reported in
Fig. S3.
Cells of themodels were washed, fixed with 4% PFA (Sigma Aldrich)
for 20 min at 4 °C, permeabilized with Triton 0.1% X-100 (Sigma Al-
drich) for 15 min, and blocked with 10% GS for 1 h. To evaluate the ex-
pression of the tight junctions, the samples were incubated 2 h at 37 °C
with 10%GS containingmonoclonal anti-tight junction protein 1 (ZO-1)
antibody (1:200; Abcam). Samples were thereafter washed in PBS and
incubated with Atto 488 goat anti-rabbit secondary antibody (1:500;
SigmaAldrich) in 10%GS at 37 °C for 1 h. Nuclei and f-actinwere respec-
tively counterstained with Hoechst 33342 (1:1000; Invitrogen) and
TRITC-phalloidin (1:200; Sigma Aldrich). Images were acquired with a
confocal microscope (C2s, Nikon).
2.10. Viability assays and therapeutic efficiency
Alamar Blue assay (Invitrogen)was performed, following themanu-
facturer's protocol, to test viability of U87 MG cells cultured for 1 day in
24-well plates (5·103 cells/cm2) and then treated for 24 and 72 h with
100 μg/ml of mPEG-DSPE-BNNTs, 100 μg/ml of CM-BNNTs, 100 μg/ml
of Dox-CM-BNNTs, or with 2.60 μg of free Dox. The amount of the
assessed free Dox (2.60 μg) corresponds to the amount of Dox loaded
in 100 μg/ml of Dox-CM-BNNT in a final volume of 400 μl of dispersion.
After the treatment, cells were washed and incubated with Alamar Blue
(1:10 dilution in culture media) for 2 h at 37 °C. The supernatant was
then collected, centrifuged, and analyzed with a multi-plate reader
(VICTOR X3 Perkin Elmer). Absorbance was measured at both λ1 =
570 nm and λ2 = 595 nm, and then λ1/λ2 ratio was calculated; the vi-
ability of cells was expressed as % following normalization with respect
to untreated controls.
Immunofluorescence against P53 and Ki-67markers was performed
to investigate apoptosis and proliferation, respectively. P53 protein, as a
result of stress factors, enters into the nucleus, activates the expression
of pro-apoptotic genes, and inhibits the expression of anti-apoptotic
genes [39]. Expression of the Ki-67 antigen in the cell nuclei occurs in
phases S, G2, andM of the cell cycle, and in G1 following themitotic di-
vision. The lack of expression of the Ki-67 antigen is observed only in
quiescent cells during the G0 phase [40,41]. Staining was performed
as described above for clathrin and caveolin-1 markers; after treatment
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for 24 and 72 h with mPEG-DSPE-BNNTs, CM-BNNTs, or Dox-CM-
BNNTs, cells were fixed with 4% PFA in PBS for 20 min at 4 °C. For Ki-
67, a primary rabbit anti-Ki-67 antibody (1:150; Abcam), and a FITC-
conjugated secondary anti-rabbit antibody (1:150; Millipore) were
used; for P53, a primary mouse anti-P53 antibody (1:100; Abcam) and
a TRITC-conjugated secondary anti-mouse antibody (1:100; Millipore)
were used. Finally, 10 min incubation with Hoechst 33342 in PBS
(1:1000; Invitrogen) was performed to stain nuclei. Imaging was per-
formedwith a C2s confocalmicroscope (Nikon); acquisition parameters
were calibrated so as to not detect the Dox fluorescence signal. NIS Ele-
ments software (Nikon)was used for the analysis of P53 and Ki-67 pos-
itive nuclei.
For investigation in fluidic conditions, SH-SY5Y (6·103 cells/cm2)
were seeded on glass coverslips and placed in 48-well plates. After
48 h of culture, differentiation was induced for 6 days by using high-
glucose DMEM supplemented with 1% FBS, 10 μM retinoic acid, and
1% P/S. C8D1A and U87 MG (6·103 cells/cm2) were instead seeded on
glass coverslips in 48-well plates just one day before the experiment.
The glass coverslips with the cells were transferred into the previously
described bioreactor and exposed to 100 μg/ml of Dox-CM-BNNTs in
HEPES-supplemented complete medium for 6 h at 37 °C with a
1.8 ml/min flow speed. After the treatment, the medium containing
Dox-CM-BNNTs was replaced with medium without nanotubes, and
cells weremaintained for 24 h at 37 °C. Finally, cells were fixed, and im-
munohistochemistry against P53 and Ki-67 followed by confocal fluo-
rescence imaging was performed as previously described.
2.11. Statistical analysis
Once the normality of data distribution was verified with the
Shapiro-Wilk test, statistical analysis was carried out with ANOVA
followed by Bonferroni post-hoc test.
3. Results and discussion
3.1. Cell membrane coating characterization
Cell membranes were extracted from the U87 MG cell line, well-
characterized and widely proposed in the literature as glioblastoma
model [42]. A schematic representation of the cell membrane extraction
and the subsequent coating is depicted in Fig. 1A. The coating of BNNTs
with deproteinated cell membrane was also performed, aiming at
assessing the role of the proteins on the homotypic targeting efficacy.
Pictures of the different BNNT preparations, giving a qualitative hint of
their stability, are shown in Supporting Information (Fig. S4).
Nanotubes coated with mPEG-DSPE (mPEG-DSPE-BNNTs) were
used as control owing to their good stability and water dispersibility,
as already described [43,44]. The functionalization procedure relies on
a simple non-covalent hydrophobic interaction between lipids and
BNNTs, both hydrophobic, that favors the formation of the coating
around BNNTs to minimize unfavorable interactions with the aqueous
solvent [43]. Lee et al. proposed a possible interaction between mPEG-
DSPE and BNNTs where the two fatty acid chains in DSPE are adsorbed
orwrapped around BNNTs, while the hydrophilic part, mPEG, allows for
the dispersion of functionalized BNNTs in water [43]. Following this de-
scription, it is possible to assume that the phospholipids in the cell
membrane extract interact in the same way with BNNTs, thanks to
their two hydrophobic fatty acid chains, whereas their hydrophilic
part (phosphate group) stabilizes the CM-BNNTs in water. Moreover,
different studies have postulated interactions between amino acids in
the proteins and BNNTs; however, the mechanism and the driving
force are not yet fully understood. One possibility is the instauration of
hydrophobic interactions between hydrophobic amino acids in proteins
and BNNTs. On the other hand, Mukhopadhyay et al. reported, through
computational investigation, interactions between BNNTs surface and
Fig. 1. A) Schematic representation of the preparation of CM-BNNTs; B) representative TEM image of CM-BNNTs; C) FTIR spectra of mPEG-DSPE (i, cyan curve), CM extract (ii, purple
curve), pristine BNNTs (iii, black curve), mPEG-DSPE-BNNTs (iv, green curve), and CM-BNNTs (v, red curve). The characteristic peaks of B\\N (yellow), as well as those of C\\H, C_O
and P_O (pink) are highlighted; D) TGA spectra presenting the percentage of weight loss (i, ii and iii) and of its derivative (iv, v and vi) in relation to the temperature increase, for
pristine BNNTs (i and iv), mPEG-DSPE-BNNTs (ii and v) and CM-BNNTs (iii and vi); E) Z-potential analysis for mPEG-DSPE-BNNs and CM-BNNTs in ultrapure water; F) size distribution
analysis presenting estimated hydrodynamic diameter in ultrapure water and in cell culture medium (DMEM+10% FBS) for mPEG-DSPE-BNNTs and CM-BNNTs. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 2. A)XPS analysis of pristine BNNTs, mPEG-DSPE-BNNTs, and CM-BNNTs; B) protein content inmPEG-DSPE-BNNTs, CM-BNNTs, and in the protease-treatedmPEG-DSPE*-BNNTs and
CM*-BNNTs (* p b .05).
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polar amino acids, like aspartic acid (Asp) and arginine (Arg), through
charge transfer and electrostatic interactions, while tryptophan (Trp),
a neutral amino acid, had no interaction with the surface of the BNNTs
[45]. Another work underlined that the benzene ring in the peptide se-
quence exhibited a strong π–π interaction with the BNNT surface [46].
In general, Waters et al. have come to the conclusion that BNNTs are
able to immobilize proteins through strong interactions with the acidic
and basic amino acids [47].
Pristine and coated BNNTs (CM-BNNTs and mPEG-DSPE-BNNTs)
were physico-chemically and morphologically characterized. The TEM
images in Fig. 1B and Fig. S5A present the morphology of uncoated
and coated BNNTs. Despite the cell membrane coating cannot be appre-
ciated with TEM, probably due to its low thickness, several physico-
chemical characterizations confirm its presence. A first hint was
provided by EDS analysis, that showed the co-localization of boron, ni-
trogen and carbon on the nanotubes (Fig. S5B), suggesting their suc-
cessful functionalization.
In the FTIR spectra presented in Fig. 1C, it is possible to observe in the
traces relative to mPEG-DSPE (i) and CM extract (ii) their typical peaks,
in particular related to the stretching of C\\H bonds in the –CH2 and –
CH3 groups (2750–3000 cm−1) and to the asymmetric vibration be-
tween phosphorus and oxygen in the PO2− group (1000–1100 cm−1).
In the trace (ii) at 1650 cm−1 it also possible to appreciate the typical
peak of (C_O) in the amide bonds, present in the amino acids of cell
membrane proteins. Differences between pristine (iii) and coated
BNNTs (iv and v) can be observed. In the range of 700–800 and
1250–1400 cm−1, the strong peaks in all the spectra can be attributed
to the stretching bonds between boron and nitrogen (B\\N). In coated
BNNTs, the spectra also show the appearance of the peaks of PO2−
group in the range 1000–1100 cm−1 (iv and v) and of CH2 and CH3
groups (2750–3000 cm−1) due to themPEG-DSPE and to the cell mem-
brane extract. In CM-BNNTs (v) it is also possible to observe the peak at
1650 cm−1 of the proteins, as already observed for the plain cell mem-
brane extract (ii). This bond, although not so easily observable, is also
present in the mPEG-DSPE-BNNTs spectrum (iv). The peak at approxi-
mately 3200 cm−1, that can be observed only in the pristine BNNTs
(iii), can be attributed to the hydroxyl groups of water molecules on
the BNNT surface. The additional peaks in both mPEG-DSPE-BNNTs
and CM-BNNTs spectra (iv and v) support the presence of an external
organic coating.
Thermogravimetric analysiswas also used as a complementary tech-
nique to show the presence of an organic layer around the BNNTs, as
well as to calculate the weight percentage of such coating. In the ther-
mograms presented in Fig. 1D,we can observe that the pristine BNNTs
start losing weight when the temperature increases above 100 °C,
resulting into a maximum weight loss of 7.5%. The initial weight loss
can be attributed to the evaporation of water molecules on the surface
of the BNNTs, while the increase above 400 °C can be attributed either
to the adsorption of nitrogen on their surface (TGA is performed
under nitrogen atmosphere) or to impurities that can lead to partial ox-
idation. TGA analysisfinally shows that the coating of bothmPEG-DSPE-
BNNTs and CM-BNNTs corresponds to approximately 20% of the total
weight.
In order to study the stability of pristine and coated BNNTs, we per-
formed dynamic light scattering measurements, evaluating the Z-
potential as well as size distribution and polydispersity. The data pre-
sented in Fig. 1E present a negative Z-potential of −10.7 ± 0.6 mV
and− 19.4 ± 1.2 mV for mPEG-DSPE-BNNTs and CM-BNNTs, respec-
tively. This negative shift of the Z-potential suggests that cellmembrane
coating may result into higher colloidal stability with respect to mPEG-
DSPE. Fig. 1F shows size distribution of coated BNNTs in water and in
DMEM +10% FBS. The average hydrodynamic diameter of coated
BNNTs (size of 357.5 ± 4.4 nm and PDI of 0.176 ± 0.015 for mPEG-
DSPE-BNNTs in water; size of 271.9 ± 45.0 nm and PDI of 0.189 ±
0.035 for mPEG-DSPE-BNNTs in DMEM +10% FBS; size of 366.5 ±
0.6 nm and PDI of 0.208 ± 0.033 for CM-BNNTs in water; size of
332.8 ± 5.5 nm and PDI of 0.213 ± 0.019 for CM-BNNTs in DMEM
+10% FBS) indicates a moderate dispersity of the coated BNNTs in
water and in complete culture medium (in both cases 0.1 ≤ PDI ≤ 0.4)
[48,49]. The slight decrease in hydrodynamic size in DMEM+10% FBS
may be due to the presence of serum proteins that further stabilize
the nanostructures.
A further demonstration of the presence of CM coating in CM-BNNTs
and the quantification of the protein amount is reported in Fig. 2. As ex-
pected, the XPS spectra presented in Fig. 2A shows the presence of B 1s
and N 1s peaks at respectively 190.6 ± 0.3 eV and 398.2 ± 0.3 eV in all
the samples. While the pristine BNNTs present low amount of carbon
and oxygen due to environmental contaminations [50], an evident P
2p doublet centered at 133.8 ± 0.3 eV (in agreement with the presence
of phospholipids [51]) was found in mPEG-DSPE-BNNTs and in CM-
BNNTs, together with stronger contributions in both the C 1s and O 1s
regions. Fitting of the high resolution XPS data revealed the presence
of C\\O, C_O, and COOH moieties in both mPEG-DSPE-BNNTs and
CM-BNNTs samples (as evidenced by the presence of peaks in the car-
bon spectra at 286.5±0.3, 288.0±0.3, and 289.0±0.3 eV, respectively
[52]), suggesting the presence of the organic coating on their surface.
Similar results could be obtained by analyzing the O 1s spectra collected
on mPEG-DSPE-BNNTs and CM-BNNTs: in both cases, the experimental
data fitting revealed the presence of two main components centered at
531.5 ± 0.3 eV and 532.7 ± 0.3 eV, respectively assigned to carboxyl
[53] and to ether groups [54] (this second component being the main
one in mPEG-DSPE-BNNTs). As a further support to the presence of
the cell membrane in CM-BNNTs samples, in the N 1s region, together
with the main peak at 398.2 eV assigned to boron nitride [55], a peak
at 400.0 ± 0.2 eV is also present, characteristic of uncharged nitrogen,
typical of amides and amines [51]. Elements detected by XPS analysis
and their % are reported in detail in Table 1.
The BCA assay (Fig. 2B) shows the presence of 91.72 ± 8.22 μg of
protein in 1 mg of CM-BNNTs. Considering that TGA revealed around
200 μg of cell membrane in 1 mg of CM-BNNTs, we can conclude that
proteins represent 45% (w/w) of the coating, a results in line with the
average protein content in cell membranes (about 50% w/w) [56]. BCA
assay also confirmed the loss of proteins in CM*-BNNTs, that were re-
moved following proteolysis of the cell membrane extracts.
3.2. CM-BNNTs homotypic targeting
The ability of CM-BNNTs to selectively target glioblastoma cells was
tested by incubating different cell lines (SH-SY5Y derived neurons,
C8D1A, U87 MG) with CM-BNNTs, mPEG-DSPE-BNNTs or CM*-BNNTs.
Confocal laser scanningmicroscopy imaging is shown in Fig. 3, while
the respective analysis of the cell area (%) occupied by nanotubes is re-
ported in Fig. 4. Results show an efficient uptake of CM-BNNTs by U87
MG cells. Just after 6 h of treatment, a remarkably higher amount of
CM-BNNTswas internalized by U87MG cells with respect to C8D1A as-
trocytes (18-folds increase) and to SH-SY5Y derived neurons (11-folds
increase). The uptake of CM-BNNTs by U87 MG cells increased after
24 h of incubation, when it resulted 36-fold higher than in SH-SY5Y de-
rived neurons and 154-fold higher with respect to C8D1A astrocytes.
Moreover, the uptake of CM-BNNTs in U87MG cells was 53-fold higher
with respect to the uptake of CM*-BNNTs. C8D1A astrocytes and SH-
SY5Y derived neurons showed scarce internalization levels for both
CM-BNNTs and mPEG-DSPE-BNNTs, suggesting a non-specific
Table 1
XPS elements quantification in pristine BNNTs, mPEG-DSPE-BNNTs, and CM-BNNTs.
Sample B (%) N (%) C (%) O (%) P (%)
BNNTs 46.5 46.9 2.4 4.2 0.0
mPEG-DSPE-BNNTs 31.0 29.4 30.1 9.4 0.1
CM-BNNTs 25.2 28.5 36.4 9.7 0.2
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Fig. 3. Targeting investigation. Confocal acquisitions of SH-SY5Y derived neurons, C8D1A astrocytes, and U87 MG cells incubated with 100 μg/ml of mPEG-DSPE-BNNTs, CM-BNNTs, or
CM*-BNNTs (f-actin in red, BNNTs in green, nuclei in blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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interaction with the two BNNT preparations. This cross-incubation ex-
periment demonstrates the relevance of the homotypic targeting for
obtaining an efficient and selective nanocarrier delivery to glioblastoma
cells. Moreover, the loss of targeting function in CM*-BNNTs revealed
the role of the protein component in mediating the membrane-
membrane recognition.
To further demonstrate that a selective homotypic targeting occurs,
ICP spectroscopy using boron as target element and flow cytometer
analysis were carried out on U87 MG, C8D1A, and differentiated SH-
SY5Y incubated for 24 h with nanotubes (CM-BNNTs, mPEG-DSPE-
BNNTs, or CM*-BNNTs). ICP analysis in Fig. 5A showed a remarkably
higher internalization of CM-BNNTs in U87 MG cells (B/P = 8.39 ±
0.42%) with respect to C8D1A (B/P = .71 ± 0.15%) and to SH-SY5Y de-
rived neurons (B/P = .44 ± 0.08%), while a scarce internalization of
mPEG-DSPE-BNNTs was observed in all the cultures (B/P = .53 ±
0.03% in U87 MG cells, B/P = .08 ± 0.01% in C8D1A cells, and B/P =
.61 ± 0.03% in SH-SY5Y derived neurons); a remarkably lower uptake
of CM*-BNNTs (B/P= 4.33 ± 0.18%) was finally found in U87MG com-
pared to CM-BNNTs (B/P = 8.39 ± 0.42%), confirming the importance
of the protein component of the cell membrane coating in the
homotypic targeting.
Similar results were obtained with flow cytometry experiments,
where DiO-stained nanotubes were exploited (Fig. 5B and C). The
highest percentage of BNNT-positive cells was found in U87 MG cul-
tures treated with CM-BNNTs (43.43 ± 0.83%), while only 11.50 ±
0.99% of U87 MG cells were positive for CM*-BNNTs. A significantly
lower amount of CM-BNNT-positive cells was detected in SH-SY5Y
(0.19 ± 0.01%) and C8D1A (15.01 ± 0.91%) cultures. Scarce levels of
mPEG-DSPE-BNNT internalization were found in all cell cultures (U87
MG 1.21 ± 0.15%, C8D1A 0.09 ± 0.01%, SH-SY5Y 0.09 ± 0.04%).
The targeting efficiency of CM-BNNTs was also investigated in dy-
namic conditions by exploiting a home-made fluidic bioreactor, that
allowed to simultaneously test the dynamic targeting of BNNTs in U87
MG cells, C8D1A astrocytes, and SH-SY5Y derived neurons (Fig. 6).
The images of this multi-chamber bioreactor during cell culture and
during dynamic experiments are shown in Fig. 6A and B, respectively.
The confocal fluorescence imaging and the analysis of the nanoparticle
internalization are reported in Fig. 6C and D, respectively. Control ex-
periments were carried out by treating cells with mPEG-DSPE-BNNTs.
After 6 h of treatment in dynamic conditions (flow speed of
1.8 ml/min for each channel), the internalization of CM-BNNTs in U87
MG cells was 160-fold higher with respect to the other cell cultures in-
cubated with CM-BNNTs, demonstrating a high affinity and selectivity
of CM-BNNTs to GBM cells. A scarce internalization of mPEG-DSPE-
BNNTs was detected in all the cell cultures. This result suggests as the
superior internalization of CM-BNNTs by U87 MG cells is not simply
Fig. 4. Quantitative internalization analysis following confocal microscopy on SH-SY5Y derived neurons, C8D1A astrocytes, and U87 MG cells incubated A) for 6 h and B) for 24 h with
100 μg/ml of mPEG-DSPE-BNNTs, CM-BNNTs, or CM*-BNNTs (* p b .05).
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due to a higher uptake rate by this cell line, but, instead, is related to the
specific surface properties of the CM coating. Altogether, these evi-
dences proved that CM-BNNTs represent an efficient targeting system,
being able to preferentially interact with the GBM cell line thanks to
self-recognition properties, thus avoiding extensive accumulation in
non-specific healthy cells.
The intracellular pathway of CM-BNNTs in U87 MG cells was inves-
tigated through confocal laser scanning microscopy (Fig. 7). The
Fig. 5. Internalization investigations on SH-SY5Y derived neurons, C8D1A astrocytes, and U87 MG cells treated for 24 h with 100 μg/ml of BNNTs with different coatings. A) ICP
investigations on boron content inside cell cultures (* p b .05); B) representative flow cytometry fluorescence data for cells after treatment with DiO-stained BNNTs: for each
distribution, populations of BNNT-positive cells are highlighted in red; C) summary of % of BNNT-positive cells for each experimental condition (* p b .05). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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analysis of the CM-BNNT localization in pinosomes, in caveolin-1-
positive organelles, and in clathrin-coated vesicles is reported in
Fig. 7A, B, and C, respectively. A scarce and similar level of CM-BNNT in-
ternalization in all the considered compartments was found. The image
analysis reported similar co-localization values (Fig. 7D), indicating that
CM-BNNTs are not internalized by a preferential route, but, rather, by
multiple internalization pathways. This phenomenon is similar to
what observed for multivalent targeting agents, and can be attributed
to the multiple and complex protein interactions that occur in
homotypic membrane-membrane recognition [57]. However, the in-
vestigation of the role of single CM receptors inmediating specific path-
ways of CM-BNNT internalization is extremely challenging, considering
that single CM receptors can be involved in multiple endocytotic path-
ways [57,58].
Lysosomal accumulation has also been analyzed (Fig. 8), since
this could affect drug release behavior from the nanovectors [59].
Confocal fluorescence imaging of the U87 MG cells incubated for 24
and 72 h with mPEG-DSPE-BNNTs or CM-BNNTs is reported in
Fig. 8A. Qualitatively, mPEG-DSPE-BNNTs resulted scarcely localized
in acidic compartments, while most of the CM-BNNTs were found in
lysosomes at both time points: at 72 h, a significantly higher co-
localization between CM-BNNTs and lysosomes (0.448 ± 0.130)
was found with respect to mPEG-DSPE-BNNTs (0.053 ± 0.04;
Fig. 8B).
Fig. 6. CM-BNNTs targeting investigations in dynamic conditions. A) Picture of the multi-compartmental bioreactor used for selective targeting experiments; B) picture of the multi-
compartmental bioreactor connected to the fluidic system; C) confocal acquisitions of SH-SY5Y derived neurons, C8D1A astrocytes, and U87 MG cells treated for 6 h with 100 μg/ml of
BNNTs in dynamic conditions (f-actin in red, BNNTs in green, nuclei in blue); D) co-localization analysis of BNNTs and cell fluorescence signals (* p b .05). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
12 D. De Pasquale et al. / Materials and Design 192 (2020) 108742
A nanovector for brain cancer therapy should be designed to be
non-invasive and able to target both the BBB and cancer cells [60].
Specific surface features, charge, shape, size, and functionalization
are required for the nanovectors to remain stably suspended in
body fluids, to perform targeting, and to cross the BBB [61,62]. BBB
crossing experiments were performed in order to test CM-BNNT
ability to overcome a BBB-mimicking in vitro endothelial barrier in
both static and dynamic conditions. The TEER values (70.05 ±
4.25 Ω cm2) indicated as the BBB models displayed good barrier
performances.
Fig. 7.Analysis of CM-BNNT internalization in U87MG cells. Confocal fluorescence detection ofA) pinosomes, B) caveolin-1, and C) clathrin;D) co-localization analysis of pinosomes/CM-
BNNTs, caveolin/CM-BNNTs and clathrin-1/CM-BNNTs fluorescence signals.
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Fig. 9A shows the amount of mPEG-DSPE-BNNTs and CM-BNNTs
that crossed the in vitro BBB in static conditions after 24 and 72 h of in-
cubation. Scarce amounts ofmPEG-DSPE-BNNTs (0.52±0.78 μg) and of
CM-BNNTs (1.14 ± 0.15 μg) were detected at 24 h; however, the
nanovector crossing significantly increased at 72 h for CM-BNNTs
(4.57 ± 0.71 μg, ~4-folds increment), but not in the case of mPEG-
DSPE-BNNTs (1.04 ± 0.78 μg).
Concerning the BBB model in dynamic conditions (Fig. 9B), CM-
BNNTs showed again a higher crossing tendency (30.47 ± 47 μg after
72 h) with respect to mPEG-DSPE-BNNTs (2.62 ± 0.92 μg).
Fig. 8. Analysis of BNNT internalization in acidic organelles (i.e., lysosomes and late endosomes) at 24 and 72 h of incubation with 100 μg/ml of mPEG-DSPE-BNNTs or CM-BNNTs. A)
Confocal fluorescence microscopy imaging: lysosomes in red, BNNTs in green, nuclei in blue; B) co-localization analysis between lysosome and BNNT signals (* p b .05). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Representative images of nanovector uptake by endothelial cells are
shown in Fig. 9C and D. Collectively, these data demonstrate that the
CM coating conferred a double functionality, improving both BBB cross-
ing and cancer cell targeting; this result is in line with recent evidences
that showed as component of cancer cell membranes promote
transcytosis through the BBB owing to a modulation of the endocytic
pathway in brain endothelial cells [63].
Proteomics analysis allowed the identification, with a FDR (false dis-
covery rate) b 1%, of proteins in CM-BNNT coating and in U87 MG/
healthy astrocyte membrane extracts; the results (data not shown) in-
dicated as themembrane proteins present in CM-BNNTs aremostly rep-
resented by cytoplasmmembrane proteins, but also, inminor extent, by
endoplasmatic reticulum membrane proteins (8.6% of the total mem-
brane proteins) and by other organelle membrane proteins (4.1% of
the total membrane proteins). “Bottleneck” analysis was performed
considering only the cell membrane proteins, which were grouped in
Venn diagram (Fig. S6). The “bottleneck” analysis individuated 117 pro-
teins that were found both in CM-BNNT coating and in U87 MG mem-
branes, but that were absent in healthy astrocyte membranes; among
them, a list of 15proteinswith specific biological function potentially in-
volved in cell-cell recognition was identified (Table 2).
Among these proteins, cadherin-2 (CDw325) and neuroplastin
(stromal cell-derived receptor 1, SDR-1) are well known in the litera-
ture for their role in homotypic recognition [64,65]. Cadherins are
calcium-dependent cell adhesion proteins that preferentially mediate
homotypic cell-cell adhesion by dimerization [66,67].When the expres-
sion of cadherin-2, β-catenin (also found and present in the final list of
our targeting proteins), and E-cadherin is altered, dysfunctions con-
nected with tumor invasion and progression may occur [64,65]. In this
context, β-catenin and N-cadherin promote the maturation of cell-cell
contacts by developing a molecular complex with the actin cytoskele-
ton, and are considered therapeutic targets and prognostic markers for
Fig. 9. BBB model crossing investigations. mPEG-DSPE-BNNTs and CM-BNNTs crossing the BBB model in A) static and B) dynamic condition (* p b .05); C) immunostaining of the
endothelial cells of the BBB model (ZO-1 in green, f-actin in red, nuclei in blue); D) representative confocal images showing BNNT uptake by endothelial cells (f-actin in red, nuclei in
blue, BNNTs in green). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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brainstem glioma [68,69]. Another protein directly involved in
homotypic recognition is neuroplastin (SDR-1), that belongs to the su-
perfamily of the cell adhesionmolecules (CAMs), and is able to promote
the cell adhesion through homophilic interactions [69].
We hypothesize that cadherin-2 and neuroplastin are the main me-
diators of homotypic targeting of CM-BNNTs toward glioblastoma cells
because of their role in binding other proteins of the same family and
in developing protein-protein junctions. However, we want to under-
line that all the proteins listed in Table 2 may cooperatively contribute
to the targeting and internalization process, since each of them is in-
volved in cell-cell interactions and in endocytosis processes [68,70–85].
3.3. CM-BNNTs as drug delivery nanovectors
The main aim of this work was to exploit CM-BNNTs to efficiently
deliver the anti-cancer drug doxorubicin in GBM cells, without affecting
healthy cells. Drug loading measurement highlighted as CM-BNNTs re-
sulted in being efficient nanocarriers, able to load 26.35 μg of Dox per
mg of nanotubes (Dox-loaded CM-BNNTs will be now indicated in the
text as Dox-CM-BNNTs), corresponding to a drug loading of 2.15% (con-
sidering the final weight after the membrane coating) and to an encap-
sulation efficiency of 95.6%.
Dox release from Dox-CM-BNNTs was studied at different experi-
mental conditions, as explained in the methods section. The release of
the drug from Dox-CM-BNNTs is slow, progressive, and pH-dependent
(Fig. 10). The cumulative release at 168 h was higher at pH 4.5
(0.54 ± 0.04 μg of drug, corresponding to 2.0% of total loaded Dox)
with respect to pH 7.4 (0.24 ± 0.01 μg of drug, corresponding to 0.75%
of total loadedDox). This is in linewith previous studies, where a higher
drug release from BNNTs in acidic conditions was found [23,86]. This
can be considered an important property of the nanocarriers, which
mostly release the drug molecules after their internalization in acidic
compartments of cells, thus avoiding the drug release in extracellular
environment. Moreover, since solid tumors are characterized by a mi-
croenvironment with increased acidity, the preferential drug release
from Dox-CM-BNNTs at low pH values can be exploited for a selective
drug release at tumor level; this property, combined with the excellent
targeting efficiency of the nanocarriers to GBM cancer cells due to the
homotypic membrane-membrane recognition, is a hint of an excellent
anti-cancer nanoplatform [87].
The anti-cancer properties of Dox-CM-BNNTs at different concentra-
tions (25, 50, 100, and 200 μg/ml) were investigated on U87 MG cells
and compared to cytotoxicity of CM-BNNTs and mPEG-DSPE-BNNTs
(Fig. 11). Results have been moreover compared to treatments with
0.65, 1.30, 2.60, and 5.26 μg/ml of free Dox, that correspond to the
drug concentrations loaded in 25, 50, 100 and 200 μg/ml of Dox-CM-
BNNTs, respectively. The viability assays indicated a low, yet significant,
decrement of metabolic activity for 5.26 μg/ml of free drug after 24 h
(Fig. 11A). At 72 h, no significant effects were observedwhen exploiting
plain BNNTs, both in case of CM-BNNTs and mPEG-DSPE-BNNTs, at all
tested concentrations (Fig. 11B). This result demonstrates the safety
and the biocompatibility of the nanocarriers, and it is in line with
other works in the literature where low BNNT cytotoxicity is reported
[88].
Dox-CM-BNNTs and free drugwere able to significantly decrease the
cell viability with respect to non-treated controls and to BNNT controls
(p b .05). This observation highlights the remarkable anti-cancer effects
of Dox-CM-BNNTs; indeed, when cultures are treatedwith 100 μg/ml of
Dox-CM-BNNTs, a remarkable decrease of cell viability was induced
with respect to non-loaded 100 μg/ml CM-BNNTs (54.1% reduction);
the anti-cancer effects of 100 μg/ml Dox-CM-BNNTs were comparable
to those induced by 2.60 μg/ml of free Dox, which caused a 49% viability
reduction compared to non-treated controls.
Immunocytochemistry analysis of the Ki-67 proliferation marker
and of the P53 apoptotic factor were carried out on U87MG cultures in-
cubated with 100 μg/ml CM-BNNTs, 100 μg/ml Dox-CM-BNNTs, or
2.60 μg/ml of free Dox; results were compared to non-treated controls
(Fig. 12). In Fig. 12A, the confocal fluorescence images of the different
experimental classes are shown at 24 and 72 h of treatment; the per-
centage of Ki-67-positive nuclei and of P53-positive nuclei are reported
in the graph of Fig. 12B. The negative control for immunostaining (with-
out primary antibody) in Dox-treated samples (2.60 μg/ml) is presented
in Fig. S7, and shows no significant fluorescence signal by using the
scanning conditions adopted for Ki-67 and P53 imaging. Immunofluo-
rescence analysis showed an elevated expression of the Ki-67 marker
in controls and in CM-BNNTs-treated cells at both time points (at
24 h, Ki-67+ nuclei in control cultures = 63.40 ± 14.21% and Ki-67+
nuclei in CM-BNNTs-treated cultures = 58.61 ± 14.91%; at 72 h, Ki-
67+ nuclei in control cultures = 63.27 ± 10.30% and Ki-67+ nuclei in
Fig. 10. Doxorubicin release from Dox-CM-BNNTs at different conditions (pH 4.5,
pH 4.5 + H2O2, pH 7.4, pH 7.4+ H2O2).
Table 2
List of cell membrane proteins selected by the “bottleneck” analysis basing on their func-
tion. This list includes proteins involved in protein-protein interaction, protein-vesicle in-
teraction, and protein-cytoplasm membrane interactions that were found in CM-BNNT
coating and in U87 MG membrane extracts, but not in healthy astrocytes membrane
extracts.
Selected CM-BNNT proteins Molecular function Ref.
Alpha adducin (ADD1) Promote assembly of
spectrin actin network
71
Cadherin-2 (CDw-325) neural cadherin, (CD
antigen CD325)
Cell-cell interaction 64,
65
CD44 antigen (CDw44) Cell-cell interaction 72
N-Cadherin Cell-cell interaction 63,
72
Catenin beta-1 (Beta-catenin) Cell adhesion regulation 74
Catenin delta-1 (Cadherin-associated Src
substrate)(CAS)(p120 catenin)
Cell adhesion regulation 85
Caveolae-associated protein 3 (Cavin-3) Regulates caveola formation
and trafficking
75
Neuroplastin (Stromal cell-derived receptor
1) (SDR-1)
Cell-cell interaction 70
Ras-related protein (Rab-23) Intracellular membrane
trafficking
76
Synaptosomal-associated protein 23
(SNAP-23)
Modulate membrane
shaping and remodeling
77
Syntaxin-16 (Syn16) (STX16) Vesicular transport 78
Tight junction protein ZO-1 (Tight junction
protein 1)
Plays a role in tight junction
and adherens junction
79,
80
Tight junction protein ZO-2 (Tight junction
protein 2)(Zona occludens protein 2)
Plays a role in tight junction
and adherens junction
81,
82
Tumor cell-derived collagenase stimulatory
factor (TCSF)(CD antigen CD147)
Cell-cell interaction 83
Zyxin (Zyxin-2) Focal adhesion 84
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CM-BNNTs-treated cultures= 59.27± 11.27%). Ki-67+ nuclearmarker
is significantly decreased in cells treated with Dox-CM-BNNTs and with
free Dox (at 24 h, Ki-67+ nuclei = 11.39 ± 3.80% in Dox-CM-BNNTs-
treated cultures; Ki-67+ nuclei = 19.94 ± 8.23% in Dox-treated cul-
tures; at 72 h, Ki-67+ nuclei = 5.2 ± 10.41% in Dox-CM-BNNTs-
treated cultures, Ki-67+ nuclei=9.33±7.80% in Dox-treated cultures).
Concerning P53, a significantly higher nuclear expression was found in
samples treated with Dox-CM-BNNTs and free Dox (at 24 h, P53+ nu-
clei = 87.53 ± 4.83% in Dox-CM-BNNTs-treated cultures and P53+ nu-
clei = 75.80 ± 8.58% in Dox-treated cultured; at 72 h, P53+ nuclei =
76.36 ± 8.33% in Dox-CM-BNNTs-treated cultures and P53+ nuclei =
79.03 ± 8.43% in Dox-treated cultured) with respect to controls (at
24 h, P53+ nuclei = 8.34 ± 6.36% in CM-BNNTs-treated cultures and
P53+ nuclei = 5.84 ± 1.87% in non-treated cultured; at 72 h, P53+ nu-
clei = 9.24 ± 4.36% in CM-BNNTs-treated cultures and P53+ nuclei =
5.77 ± 2.42% in non-treated cultures). These results highlight an effi-
cient pro-apoptotic and anti-proliferative effect of the Dox-CM-BNNT
treatment, which is in line with the observed remarkable decrease of
cell survival. The anti-cancer efficacy of Dox-CM-BNNTs can be attrib-
uted to toxicity of the Dox released from the nanocarriers, since no sig-
nificant anti-proliferative and pro-apoptotic effects were elicited by the
plain CM-BNNTs. In this regard, the elevated internalization of the CM-
coated nanocarriers into the acidic organelles likely promotes a
sustained release of Dox in the cells.
In order to evaluate the effective potential of Dox-CM-BNNTs to in-
duce selective and targeted apoptosis, we simultaneously tested the
drug-loaded nanocarriers on the three different cell lines (U87 MG,
C8D1A, and differentiated SH-SY5Y), by exploiting the aforementioned
home-made bioreactor. After 6 h of treatment in dynamic conditions
(flow speed 1.8 ml/min), samples were washed to remove CM-BNNTs
and Dox-CM-BNNTs that were non-associated to the cells, and subse-
quently incubated for 72hwithmediumwithout nanotubes. Thereafter,
samples were fixed and immunostained against Ki-67 and P53markers
(confocal fluorescence microscopy imaging is shown in Fig. 13A). The
percentages of nuclei positive for Ki-67 (Ki-67+), P53 (P53+), or double
negative for these markers (Ki-67−/P53−) are reported in the graph of
Fig. 11. Cell viability assay on U87 MG cells treated with plain nanocarriers (mPEG-DSPE-BNNTs or CM-BNNTs), Dox-CM-BNNTs, and free doxorubicin for A) 24 h and B) 72 h (* p b .05).
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Fig. 13B. A significantly higher percentage of P53+ nuclei was found in
U87 MG cells treated with Dox-CM-BNNTs (22.31 ± 3.45%) with re-
spect to the U87 MG cells incubated with CM-BNNTs (2.83 ± 1.69%;
p b .05). These results, observed at 6 h of treatment in dynamic condi-
tions, indicate as early stage apoptosis was induced [89]. Conversely, a
significant decrease of Ki-67+ cells was found in U87 MG cells exposed
to Dox-CM-BNNTs (11.84 ± 5.13%) compared to CM-BNNT (63.09 ±
7.21%; p b .05). Most importantly, the P53 and Ki-67 expression was
not significantly affected by the Dox-CM-BNNT treatment in the other
cell lines. Specifically, the percentage of P53+ cells resulted extremely
low after dynamic treatment with CM-BNNTs or Dox-CM-BNNTs (for
SH-SY5Y derived neurons, P53+ cells resulted 0.1 ± 0.2% and 0.7 ±
0.4%, respectively; for C8D1A, P53+ cells resulted 1.0 ± 1.7% and
2.60 ± 0.5%, respectively), and Ki-67 proliferation marker was not sig-
nificantly affected after treatment with Dox-CM-BNNT with respect to
CM-BNNTs-treated controls (for SH-SY5Y derived neurons, Ki-67+
cells resulted 31.2 ± 12.8% and 27.6 ± 1.9%, respectively; for C8D1A,
Ki-67+ cells resulted 46.5 ± 12.1% and 48.6 ± 18.1%, respectively;
p b .05). This result can be attributed to the scarce internalization level
of the CM-BNNTs in the healthy cell lines; moreover, it demonstrates
the specific anti-cancer efficacy of Dox-CM-BNNTs against GBM cells
and the extremely relevant potential of the homotypic targeting ap-
proach in reducing the chemotherapy-induced side effects (54.1% re-
duction of cell viability in GBM cells versus no significant apoptotic
effects in SH-SY5Y and C8D1A control cell lines).
Similar results on homotypic targeting and selective death have
been recently obtained by Wang et al. on melanoma cells [90]. In this
work, a complex hybrid nanosystem has been obtained by coating
Dox-loaded hollow copper sulfide nanoparticles with a mix of mem-
branes derived from red blood cells and B16-F10 melanoma cells
fused together. This nanosystem (CuS@[RBC\\B16]) resulted efficiently
and selectively internalized by B16-F10 cells; specifically, a 7/9-folds
higher fluorescence intensity was detected in B16-F10 melanoma cells
with respect to other cell lines (HT1080, NHDF, and A549 cells) upon
Fig. 12. Immunocytochemistry investigations on Ki-67 and P53 expression inU87MGcells treated for 24 and 72hwith CM-BNNTs, Dox-CM-BNNTs, and freeDox.A)Confocalfluorescence
microscopy imaging of Ki-67 (in green), P53 (in red) and nuclei (in blue); B) graph showing the percentage of Ki-67+ and P53+ nuclei (* p b .05 for P53+ nuclei; # p b .05 for Ki-67+
nuclei). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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4 h of incubation with DiI-stained CuS@[RBC\\B16]. Despite Dox-
loaded CuS@[RBC\\B16] displayed an anti-cancer efficacy (24.2% of
cells death) lowerwith respect to our Dox-loaded CM-BNNTs (54.1% re-
duction of cell viability), authors exploited the near infra-red
photothermal conversion property of CuS for obtaining a synergic
hyperthermal and chemotherapy treatment of melanoma cells
(resulting into a 94.5% of cell death). In the context of combined
physico-chemical anti-cancer treatments, it is worth mentioning that
BNNTs can also be exploited as a boron reservoir in boron neutron cap-
ture therapy (BNCT) [91]. This anti-cancer approach, that exploits
epithermal neutron beam radiation, has been already successfully
tested in clinical trials, with improved survival in patients with newly
diagnosed glioblastoma (mean overall survival of 20.7 months with
2 years survival of 25% for patients treated with BNCT) [92]. 10B-
enriched CM-BNNTs would, therefore, represent a double carrier of
both B and Dox; future works may be devoted to investigate the syner-
gic effect of BNCT and chemotherapy for the treatment of glioblastoma
multiforme by taking advantage of the outstanding homotypic targeting
efficacy in precision medicine.
Another remarkable example of nanoparticle targeting to cancer
cells via homotypic recognition is represented by Dox-loaded gold
nanocages (AuNs) coated with 4T1 CM, that have been exploited
by Sun et al. for inhibiting the growth of breast cancer [93]. Similarly
to the work of Wang et al., in this research a photothermal therapy
was carried out by exploiting near infra-red radiation in order to in-
duce hyperthermia and to enhance the anti-cancer efficacy. Interest-
ingly, the combined stimulation was able not only to significantly
reduce the volume of the tumor mass, yet also to decrease the meta-
static capability of breast cancer in terms of number of pulmonary
metastatic nodules.
Other nanotechnology-based approaches adopting cancer cell self-
recognition for selective cell death also include CM-encapsulated mag-
netic nanoparticles loaded with Dox, CM-cloaked Dox with poly(lac-
tic-co-glycolic acid) nanoparticles for the treatment of hepatocellular
carcinoma, and paclitaxel-loaded CM-coated polymeric nanoparticles
for the therapy of breast cancer and of its metastasis [27,94,95].
Obviously, the excellent targeting capabilities deriving from
homotypic recognition can also be exploited for improving the diagnos-
tic capabilities of different nanoprobes. In this specific context, the
group of Pang demonstrated the bioimaging in the second near infra-
red window of breast cancer in mice by using Ag2Te quantum dots en-
capsulated within cancer CM; specifically, improved nanoprobe accu-
mulation at tumor sites and higher tumor-to-normal tissue signal
ratio were demonstrated thanks to the CM coating [96].
Fig. 13. Selective apoptosis of U87MG cancer cells elicited by Dox-CM-BNNTs in dynamic conditions. A) Immunofluorescence imaging of Ki-67 (in green) and P53 (in red)markers in SH-
SY5Y derived neurons, C8D1A astrocytes, and U87MG cells treatedwith CM-BNNTs or with Dox-CM-BNNTs in dynamic conditions; B) graph showing the percentage of Ki-67+ and P53+
nuclei in the different experimental conditions (* p b .05 for P53+ nuclei; # p b .05 for Ki-67+ nuclei). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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Finally, it is worth some consideration about the size and the non-
biodegradability of the proposed nanoplatform. First of all, we have to
highlight as biodistribution and pharmacokinetics of nanoparticles
with sizes around 300 nmmay generate concerns when intravenously
administered, due to filtration and accumulation in the liverwith conse-
quent reduced circulation half-life, decreasing the chances of reaching
the tumor site [97,98]. Moreover, no (or scarce) biodegradation of
BNNTs can arise problems of long-term accumulation and inflammatory
response. This notwithstanding, several studies by different groups, in-
cluding ours, have shown satisfactory results in terms of biodistribution,
circulation half-life, and biocompatibility [99,100] of BNNT-based sys-
tems owning similar sizes, all features that make these tubular struc-
tures excellent candidates for theranostic applications. Moreover, in
our work we demonstrated as CM-BNNTs selectively target tumor
cells, with high efficiency and with very low uptake by the other cell
lines: results that strongly suggest reduced undesired effects originated
by aspecific accumulation.
4. Conclusion
Specific targeting of cancer cells represents an important challenge
for nanomedicine to promote tumor regression by reducing the side ef-
fects of anti-cancer drugs. In this context, homotypic recognition is a
new promising targeting strategy that exploits the self-recognition
properties of cancer cells. In this work, we developed a new
nanoplatform based on Dox-CM-BNNTs for the targeting and treatment
of glioblastoma cells in vitro. The proposed nanocarriers resulted in
being an efficient drug delivery systems characterized by excellent
in vitro BBB crossing, targeting efficiency, and pH-dependent release
properties. The proteomic analysis allowed identifying the key role of
cadherin-2 (CDw-325) and neuroplastin (SDR-1) in homotypic recogni-
tion of CM-BNNTs by glioblastoma cells. Finally, strong anti-cancer effi-
cacy of Dox-CM-BNNTs in U87 MG cells, without significant side effects
in healthy cells, was demonstrated in a complex in vitromulti-cellular
and dynamic model. Altogether, these results demonstrated as the pro-
posed nanoplatform is a promising candidate in anti-cancer therapy.
This is of course a first step toward actual therapeutic applications,
andwe are conscious that indeed in vivo testingwill be necessary before
claiming success of such approach. Futureworkswill be thus devoted to
investigate the blood-brain barrier crossing efficiency of CM-BNNTs and
to validate their targeting efficiency on in vivomodels of glioblastoma
multiforme.
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